In March I wrote about Phase IIa results of a novel NSAID-like drug ATB-346 (now called otenaproxesul), which is structurally and functionally similar to naproxen (Aleve). But the non-opioid drug lacks its gastrointestinal side effects, especially ulcers. Now Phase IIb results are in and it still looks good. Will it become the first member of a novel class of pain drugs? We could sure use it. A summary of the company's report to shareholders.
When I wrote about "Magic Aleve" -- a derivative of Aleve/naproxen that appears to be both G.I.-friendly and a more potent analgesic/antiinflammatory than Aleve itself -- a number of questions arose. Dr. John Wallace, CSO of Antibe, which is developing the drug called ATB-346, kindly agreed to answer them.
There hasn't been a material advance in the pharmacological treatment of pain since the 1890s, when heroin and aspirin were invented. That may change if an experimental drug being developed by a Toronto-based drug company keeps performing in advanced clinical trials. This could be huge.
Alcohol is both good and bad. Makes some happy, others sad. It amplifies joy, or exacerbates decline. It alienates, it coalesces. It de-stresses, stresses, calms and kills. But you know what? You are the variable. So, then is moderation sexy? Explore your prescription.